Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057


News SummaryMost relevantAll newsSector newsTweets 

Shire : Files 8K - Other Events

share with twitter share with LinkedIn share with facebook
share via e-mail
02/17/2017 | 07:24pm CEST

Shire PLC (SHPG) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on February 17, 2017.

Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010317001531/dp73113_8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010317001531/0000950103-17-001531-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE
02:02p SHIRE : To present new data at isth 2017 to advance the standard of care in hemo..
06/22 SHIRE : FDA approves new Shire drug for ADHD
06/22 SHIRE : announces EMA validation of VEYVONDI™ Marketing Authorization Appl..
06/21 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
06/21 SHIRE : U.S. FDA Approves Mydayis™ (mixed salts of a single-entity ampheta..
06/09 SHIRE : New Therapeutics Research Study Results Reported from Shire Pharmaceutic..
06/07 FTSE slips as markets brace for election
06/01 SHIRE PLC (NASDAQ : SHPG) Files An 8-K Other Events
06/01 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
05/31 FTSE 100 retreats from peak as Shire and Mediclinic ail
More news
Sector news : Pharmaceuticals - NEC
04:34pDJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
01:48pDJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
01:15pDJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
12:20p China's ICBC says checks of loans to big acquirers are routine
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:10a SNIPPET ROUNDUP : CSL Makes HAE And Shire Extends ADHD Franchise
06/22 EMA accepts Shire's marketing application for recombinant therapy for inherit..
06/21 FDA OKs Shire's Mydayis for ADHD; shares up 1% premarket
06/21 AMICUS THERAPEUTICS : Elucidating The Bullish And Bearish Claims
06/20 Total Worldwide Drug Sales Forecast To Fall As Uncertainty Hits Pharma
Financials ($)
Sales 2017 15 120 M
EBIT 2017 5 665 M
Net income 2017 2 575 M
Debt 2017 18 750 M
Yield 2017 0,64%
P/E ratio 2017 17,44
P/E ratio 2018 12,93
EV / Sales 2017 4,76x
EV / Sales 2018 4,20x
Capitalization 53 196 M
More Financials
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 73,4 $
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
Matt Walker Head-Technical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-1.24%53 196
JOHNSON & JOHNSON17.10%366 496
NOVARTIS7.69%225 516
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
MERCK AND COMPANY12.15%180 576
More Results